Abbott ABT announced the availability of FreeStyle LibreLink app in Europe for use in smartphones(both iPhone and Android). Notably, diabetes patients using the ...

The FDA granted clearance for a standalone reader to be used for glucose management with the FreeStyle Libre 3 CGM. Users will have the option to use either the reader or the device’s smartphone app.

The Abbott FreeStyle Libre 2 can be used as a real-time continuous glucose monitor (CGM) with an upgrade to the FreeStyle LibreLink app. Please note, the below information comes with a critical update ...

The Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS App for use with the FreeStyle Libre 2 14-day glucose sensors in individuals 4 years of age and older with diabetes. The ...

MISSISSAUGA, Ontario, Oct. 4, 2018 /CNW/ -- Abbott (NYSE: ABT) announced today the company has received the Health Canada license of its FreeStyle LibreLink mobile app for use with compatible iOS ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

Some users in the UK are experiencing a disruption in the functionality of the FreeStyle Libre 2 blood sugar monitoring app following an update, and it underscores the vulnerability of our digital ...

(RTTNews) - Abbott said that the U.S. Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones, providing a comprehensive digital offering for its ...

Beta Bionics' flagship product, the iLet Bionic Pancreas, is an autonomous insulin delivery system that streamlines diabetes management and reduces the burden on patients, caregivers and physicians.

The US Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones. The new app works with the FreeStyle Libre 2 with optional glucose alarms, which ...